ZURICH, Switzerland, April 19, 2024 (GLOBE NEWSWIRE) -- Today, Life Science Cares, a collective effort of the life science industry to reduce the impact of poverty and inequality in their communities, launched in Switzerland, marking its first expansion as an independent association into geographies outside of the United States.
“We are excited to launch Life Science Cares Switzerland (LSCS) today, in time, to engage with the local community at the upcoming Swiss Biotech Day in Basel,” said Nadine Zahnd, Managing Director of LSCS. “At the heart of our life sciences community is the overwhelming sense to act and do good. We are building bridges between Swiss Life Science Organizations and local charitable organizations for individuals who may otherwise fail to access the opportunities afforded to so many of us.”
In Switzerland in 2021, 1.24 million people, including many families are considered at the brink of poverty. Those affected are at risk of losing their social contacts and often suffer from psychological and physical health problems. Children in such families face often insurmountable obstacle to reach their full potential. It is the mission of LSCS to break this cycle and offer a path to unlock opportunity.
At the Swiss Biotech Day, LSCS will be showcased in the Plenary Session on 22 April 2024 and in a dedicated Panel discussion featuring the Swiss Red Cross, Cooley LLP, Novartis, the Swiss Biotech Association (SBA) and Molecular Partners at 4.30 pm at Marriott Hotel in Basel. Information will be available for everyone who wishes to contribute to our mission at the SBA Booth.
The Board of LSCS will be constituted by Isabel Dalli, Novartis; Sarah MacDonald, CEO LSC, Inc.; Dorothea Bergler, Swiss Red Cross; Patrick Amstutz, Swiss Biotech Association / Molecular Partners; Dieter Gericke, Homburger; Christoph Schmidt, up&up communication.
Founding Members include Ulf Grawunder, Founder and former CEO of NBE Therapeutics; Bill Burns, former CEO of Roche Pharmaceuticals; Dominik Höchli, former Head of Global Medical Affairs at Abbvie; Patrick Amstutz, CEO of Molecular Partners and Chairman of Swiss Biotech Association, as well as Molecular Partners, OM Pharma, the Swiss Biotech Association, HBM Healthcare Investments and others.
About Life Science Cares Switzerland:
Life Science Cares Switzerland brings together the life science community and local non-profit organizations to build bridges for people with limited opportunities in our country. Our goal is to provide access to education and opportunity for all who wish to develop beyond their own limitations – by connecting the talents and minds of the life science community with the hearts of non-profit organizations. Learn more at www.lifesciencecares.ch
Contact:
Life Science Cares Switzerland
Nadine Zahnd-Straumann
Scheuchzerstrasse 35
CH-8006 Zürich
| Last Trade: | US$3.95 |
| Daily Change: | -0.33 -7.71 |
| Daily Volume: | 2,761 |
| Market Cap: | US$145.600M |
April 25, 2025 March 06, 2025 January 12, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
